Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.

Breast cancer research and treatment - 1 Aug 2017

Turashvili Gulisa, Brogi Edi, Morrow Monica, Hudis Clifford, Dickler Maura, Norton Larry, Wen Hannah Y

Abstract excerpt

BACKGROUND/PURPOSE: The 21-gene recurrence score (RS) assay predicts the likelihood of distant recurrence and chemotherapy benefit in early-stage, estrogen receptor (ER)-positive, HER2-negative breast cancer. Data on the RS of special histologic subtypes of invasive breast carcinoma with favorable prognosis are limited. METHODS: We reviewed our institutional database to identify patients with special histologic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Mucinous
Share to Carcinoma, Papillary

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Databases, Factual

Share to Disease-Free Survival

Share to Neoplasm Invasiveness

Share to Precision Medicine

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Source

Open in PubMed Open full text

Identifiers

PMID: 28577081
DOI: 10.1007/s10549-017-4326-1
PMCID: PMC5572649

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.PMID 28577081Read ↗

Favorable Locoregional Control in Clinically Node- Negative Hormone-receptor Positive Breast Cancer With Low 21-gene Recurrence Scores: a Single Institutional Study With 10-year Follow-upSemantic proximity Read ↗

21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.Semantic proximity Read ↗

Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score.Semantic proximity Read ↗

The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer: A National Cancer Database StudySemantic proximity Read ↗

Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer.Semantic proximity Read ↗

21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.Semantic proximity Read ↗

Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.Semantic proximity Read ↗

Utilization and Outcomes of the 21-Gene Recurrence Score in pN2 Breast Cancer PatientsSemantic proximity Read ↗

The Clinical Impact of 21-Gene Recurrence Score on Treatment Decisions for Patients with Hormone Receptor-Positive Early Breast Cancer in KoreaSemantic proximity Read ↗

A 95-gene Signature Stratifies Recurrence Risk of Invasive Disease in ER-positive, HER2-negative, Node-negative Breast Cancer With Intermediate 21-gene Signature Recurrence ScoresSemantic proximity Read ↗

Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen.Semantic proximity Read ↗

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.